单位：[1]Department of Intensive Care Medicine, Tampere University Hospital,University of Tampere, 10 Bio katu, Tampere 33014, Finland[2]Department ofCritical Care Medicine, University of Pittsburgh Medical School, 3550 TerraceStreet, Pittsburgh, PA 15261, USA[3]Department of Emergencies and CriticalCare, Rikshospital of Oslo University, PO Box 4950, Nydalen, Oslo 0424,Norway[4]Department of Gastroenterology, Beijing Friendship Hospital,Capital Medical University, 95 Yong An Road, Beijing 100050, China临床科室国家中心消化分中心消化内科首都医科大学附属北京友谊医院[5]Institutefor Clinical Medicine, University of Oslo, Blindern, Oslo 0316, Norway
Ethyl pyruvate (EP) is a simple derivative of pyruvic acid, which is an important endogenous metabolite that can scavenge reactive oxygen species (ROS). Treatment with EP is able to ameliorate systemic inflammation and multiple organ dysfunctions in multiple animal models, such as acute pancreatitis, alcoholic liver injury, acute respiratory distress syndrome (ARDS), acute viral myocarditis, acute kidney injury and sepsis. Recent studies have demonstrated that prolonged treatment with EP can ameliorate experimental ulcerative colitis and slow multiple tumor growth. It has become evident that EP has pharmacological anti-inflammatory effect to inhibit multiple early inflammatory cytokines and the late inflammatory cytokine HMGB1 release, and the anti-tumor activity is likely associated with its anti-inflammatory effect. EP has been tested in human volunteers and in a clinical trial of patients undergoing cardiac surgery in USA and shown to be safe at clinical relevant doses, even though EP fails to improve outcome of the heart surgery, EP is still a promising agent to treat patients with multiple inflammatory organ injuries and the other clinical trials are on the way. This review focuses on how EP is able to ameliorate multiple organ injuries and summarize recently published EP investigations.
基金：
Sigrid Juselius Funding in Finland; South-Eastern Norway Regional Health Authority [2013121]
第一作者单位：[1]Department of Intensive Care Medicine, Tampere University Hospital,University of Tampere, 10 Bio katu, Tampere 33014, Finland[2]Department ofCritical Care Medicine, University of Pittsburgh Medical School, 3550 TerraceStreet, Pittsburgh, PA 15261, USA[3]Department of Emergencies and CriticalCare, Rikshospital of Oslo University, PO Box 4950, Nydalen, Oslo 0424,Norway
通讯作者：
通讯机构：[1]Department of Intensive Care Medicine, Tampere University Hospital,University of Tampere, 10 Bio katu, Tampere 33014, Finland[2]Department ofCritical Care Medicine, University of Pittsburgh Medical School, 3550 TerraceStreet, Pittsburgh, PA 15261, USA[3]Department of Emergencies and CriticalCare, Rikshospital of Oslo University, PO Box 4950, Nydalen, Oslo 0424,Norway
推荐引用方式(GB/T 7714)：
Yang Runkuan,Zhu Shengtao,Tonnessen Tor Inge.Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries[J].JOURNAL of INFLAMMATION-LONDON.2016,13:doi:10.1186/s12950-016-0144-1.
APA：
Yang, Runkuan,Zhu, Shengtao&Tonnessen, Tor Inge.(2016).Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries.JOURNAL of INFLAMMATION-LONDON,13,
MLA：
Yang, Runkuan,et al."Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries".JOURNAL of INFLAMMATION-LONDON 13.(2016)
